Etidronic acid and its calcium-comprising complexes in the treatment of experimental osteoporosis in estrogen-deficient rats

  • V. V. Povoroznyuk
  • N. V. Grygorieva
  • V. I. Pekhnyo
  • H. Resch
  • O. M. Kozachkova
  • N. V. Tsaryk
Science in CEE countries



The aim of this study was to investigate the composition, stability, and biological activity of the complexes formed in solution upon interaction of calcium (Ca) ions with etidronic acid (EA), and to compare their effects on bone mineral density (BMD) in estrogen-deficient rats with osteoporosis.

Materials and methods

The study was conducted on 40 female Wistar rats. Osteoporosis was modeled by bilateral oophorectomy and therapy was started 4 months after surgery. Four groups were under study: the first group did not receive any osteoporotic treatment, only supplementation of Ca/vitamin D (D) in their diet. The second group received a single parenteral dose of EA with Ca/D supplementation. The third group received a Ca complex of EA (Ca-EA) without additional use of Ca/D. The fourth group received Ca-EA with Ca/D. Bone parameters (BMD and bone mineral content [BMC] in spine and total body) were measured by X‑ray densitometry using Prodigy (GE Medical systems, Model 8743, 2005; USA; program “Experimental animals”) thrice (before treatment, after 1 and 3 months of follow-up).


Therapy with EA and Ca/D showed significant differences in total body BMD (tbBMD) only after 3 months. We established reliable changes in spine BMD (sBMD) and tbBMD after 1 and 3 months of treatment in group 3 rats: administration of Ca-EA with Ca/D had positive effects on sBMD at 1 and 3 months, and on tbBMD after 3 months. We did not establish any significant changes between sBMD and tbBMD after 1 and 3 months of therapy dependent on additional Ca/D supplementation (groups 3 and 4).


We showed a positive effect of the studied Ca-EA complexes on the BMD and BMC indices, with or without additional supplementation of Ca/D. More explicit dynamics of indices were observed in the group of animals treated with Ca-EA without additional Ca/D after 1 and 3 months of follow-up.


Oophorectomy Rats, Wistar Calcium-comprising complexes of etidronic acid Bone mineral density 



We are grateful for the collaboration of the group of scientists of D. F. Chebotarev Institute of Gerontology of NAMS Ukraine (Kyiv, Ukraine) who performed bilateral oophorectomy and DXA measurement.

Compliance with ethical guidelines

Conflict of interest

V.V. Povoroznyuk, N.V. Grygorieva, V.I. Pekhnyo, H. Resch, O.M. Kozachkova, and N.V. Tsaryk declare that they have no competing interests.

All applicable international, national, and/or institutional guidelines for the care and use of animals were followed.


  1. 1.
    Kanis JA, McCloskey EV, Johansson H, Cooper C, Rizzoli R, Reginster J‑Y, Scientific Advisory Board of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO), Committee of Scientific Advisors of the International Osteoporosis Foundation (IOF) (2013) European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int 24:23–57. CrossRefPubMedGoogle Scholar
  2. 2.
    Camacho PM, Peak SM, Binkley N, Clarke BL, Harris ST, Hurley DL, Kleerekoper M, Lewiecki EM, Miller PD, Narula HS, Pessah-Pollack R, Tangpricha V, Wimalawansa SJ, Watts NB (2016) American Association of Clinical Endocrinologists and American College of Endocrinology Clinical Practice Guidelines for the diagnosis and treatment of postmenopausal osteoporosis—2016—Executive Summary. Endocr Pract 22(9):1111–1118. CrossRefPubMedGoogle Scholar
  3. 3.
    Povoroznyuk VV, Grygorieva NV, Orlyk TV et al (2014) Osteoporosis in the practice of internist doctor. Express, Kyiv (Russian)Google Scholar
  4. 4.
    Chan CK, Mason A, Cooper C, Dennison E (2016) Novel advances in the treatment of osteoporosis. Br Med Bull 119(1):129–142. CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Moore SN, Tanner SB, Schoenecker JG (2015) Bisphosphonates: from softening water to treating PXE. Cell Cycle 14(9):1354–1355. CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Russell RG (2011) Bisphosphonates: the first 40 years. Bone 49(1):2–19. CrossRefPubMedGoogle Scholar
  7. 7.
    Ebetino FH, Hogan AM, Sun S, Tsoumpra MK, Duan X, Triffitt JT, Kwaasi AA, Dunford JE, Barnett BL, Oppermann U, Lundy MW, Boyde A, Kashemirov BA, McKenna CE, Russell RG (2011) The relationship between the chemistry and biological activity of the bisphosphonates. Bone 49(1):20–33. CrossRefPubMedGoogle Scholar
  8. 8.
    Zhou J, Ma X, Wang T, Zhai S (2016) Comparative efficacy of bisphosphonates in short-term fracture prevention for primary osteoporosis: a systematic review with network meta-analyses. Osteoporos Int 27(11):3289–3300. CrossRefPubMedGoogle Scholar
  9. 9.
    Amiche MA, Albaum JM, Tadrous M, Pechlivanoglou P, Lévesque LE, Adachi JD, Cadarette SM (2016) Efficacy of osteoporosis pharmacotherapies in preventing fracture among oral glucocorticoid users: a network mEA-analysis. Osteoporos Int 27(6):1989–1998. CrossRefPubMedGoogle Scholar
  10. 10.
    Tartari T, Guimarães BM, Amoras LS, Duarte MA, e Souza SPA, Bramante CM (2015) Etidronate causes minimal changes in the ability of sodium hypochlorite to dissolve organic matter. Int Endod J 48(4):399–404. CrossRefPubMedGoogle Scholar
  11. 11.
    Council of Europe (1986) European convention for the protection of vertebrate animals used for experimental and other scientific purpose: Council of Europe 18.03.1986. Council of Europe, StrasbourgGoogle Scholar
  12. 12.
    Povoroznyuk VV, Deduh NV, Grygorieva NV, Gopkalova IV (2012) Experimental osteoporosis. Express, Kyiv (Russian)Google Scholar
  13. 13.
    Afonin EG, Aleksandrov GG, Ilyinsky AL (2000) Diprotonated 1‑hydroxyethane-1,1-diphosphonate of calcium. Russ J Inorg Chem 45(6):961–966Google Scholar
  14. 14.
    Gómez-Alcántara MM, Cabeza A, Martínez-Lara M, Aranda MA, Suau R, Bhuvanesh N, Clearfield A (2004) Synthesis and characterization of a new bisphosphonic acid and several mEAl hybrids derivatives. Inorg Chem 43(17):5283–5293CrossRefPubMedGoogle Scholar
  15. 15.
    De Colli M, Tortorella P, Marconi GD, Agamennone M, Campestre C, Tauro M, Cataldi A, Zara S (2016) In vitro comparison of new bisphosphonic acids and zoledronate effects on human gingival fibroblasts viability, inflammation and matrix turnover. Clin Oral Investig 20(8):2013–2021CrossRefPubMedGoogle Scholar
  16. 16.
    Ferrer-Casal M, Li C, Galizzi M, Stortz CA, Szajnman SH, Docampo R, Moreno SNJ, Rodriguez JB (2014) New insights into molecular recognition of 1,1-bisphosphonic acids by farnesyl diphosphate synthase. Bioorg Med Chem 22(1):398–405CrossRefPubMedGoogle Scholar
  17. 17.
    Komisarenko SV, Sharykina NI, Lozynskyi MO, Lozynskyi MO, Karlova NP, Kudriavtseva IH, Kuzmenko IY, Borysevych AM, Yezerska LY (2001) Patent number UA 40714. Published 15.08.2001. Antitumor agent (mebiphon) RussianGoogle Scholar

Copyright information

© Springer-Verlag GmbH Austria, ein Teil von Springer Nature 2017

Authors and Affiliations

  • V. V. Povoroznyuk
    • 1
  • N. V. Grygorieva
    • 1
  • V. I. Pekhnyo
    • 2
  • H. Resch
    • 3
  • O. M. Kozachkova
    • 2
  • N. V. Tsaryk
    • 2
  1. 1.State Institution D. F. Chebotarev Institute of GerontologyUkrainian National Academy of SciencesKyivUkraine
  2. 2.V. I. Vernadsky Institute of General and Inorganic ChemistryUkrainian National Academy of SciencesKievUkraine
  3. 3.St. Vincent Hospital Vienna, Academic Teaching HospitalMedical University of ViennaViennaAustria

Personalised recommendations